« Return to News | Awards & Advancement

Northwest Biotherapeutics change, expands management team

Friday, June 10, 2011 11:28 AM

Northwest Biotherapeutics (NWBT), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities, has added several executives to its management team.

Linda Powers, Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, an executive in the field of cancer immune therapies, joins as Chief Operating Officer. Dr. Alton Boynton, the scientific founder of NWBT and has served as CEO since May 2007, is returning to his position as Chief Scientific Officer. Les Goldman, a former longtime partner at Skadden, Arps specializing in advanced technology commercialization, has been appointed Senior Vice President, Business Development.

Dr. Maida brings more than 20 years of experience in building oncology companies, with expertise in the business and financial aspects, the clinical and regulatory aspects and the underlying science. He has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings. He served as CEO of CancerVax, an early leader in cancer vaccines, raising the company's first $30 million of funding. Dr. Maida also served as global head of Oncology for a CRO. He recently completed and in 2010 received a Ph.D. in Tumor Immunology. 

Goldman was a partner at law firm Skadden, Arps for over 30 years, specializing in a wide array of advanced technologies and their commercialization. He also serves as an advisor to a number of other technology companies. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.